Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6067687 | 0.85 | HSD11B1 (0.55) | HSD11B1CNR2PDK2CES1NOTUM | |
| SCHEMBL2492272 | 0.84 | HSD11B1 (0.46) | HSD11B1NOTUMALDH1A1HPGDAR | |
| SCHEMBL2036638 | 0.81 | HSD11B1 (0.40) | HSD11B1CNR2PDK2CES1ALDH1A1 | |
| SCHEMBL2597833 | 0.76 | HSD11B1 (0.51) | HSD11B1CNR2PDK2CES1ALDH1A1 | |
| SCHEMBL67468 | 0.74 | ALDH1A1 (0.43) | HSD11B1PDK2NOTUMALDH1A1KIF11 | |
| SCHEMBL2000756 | 0.73 | HSD11B1 (0.46) | HSD11B1CNR2PDK2CES1ALDH1A1 | |
| SCHEMBL28223418 | 0.73 | HSD11B1 (0.49) | HSD11B1CNR2PDK2ALDH1A1SCN9A | |
| SCHEMBL2491458 | 0.73 | PDK2 (0.41) | HSD11B1PDK2CES1NOTUMALDH1A1 | |
| SCHEMBL2093777 | 0.72 | ALDH1A1 (0.32) | HSD11B1NOTUMALDH1A1HPGD | |
| SCHEMBL16340864 | 0.72 | HSD11B1 (0.44) | HSD11B1CNR2PDK2CES1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664597-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | claimed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1511734-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-05-10 | — | — | EP | claimed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | claimed |
| JP-2005523312-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | claimed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | claimed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1554265-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004024086-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | HSD11B1 1235/4885CNR2 4295/4885PDK2 411/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | HSD11B1 1079/4885CNR2 3704/4885PDK2 498/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | HSD11B1 1079/4885CNR2 3704/4885PDK2 498/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | HSD11B1 1079/4885CNR2 3704/4885PDK2 498/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | HSD11B1 1079/4885CNR2 3704/4885PDK2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.